Women with prior GDM have glucose and lipid metabolism disorders in the 1st trimester. Limited reduction of GWG before oral glucose tolerance test (OGTT) was insufficient to offset the adverse effects of glucose and lipid metabolism disorders in women with previous GDM (Diabetology & Metabolic Syndrome)
Diabetes News
Category: Gestational
Effectiveness of antidiabetic agents for treatment of gestational diabetes: A methodological quality assessment of meta-analyses and network meta-analysis
This review study of available literature shows that metformin can be a superior option in most neonatal and maternal adverse pregnancy outcomes in women with gestational diabetes mellitus; the results need to be further updated by including future more qualified studies (Journal of Diabetes Investigation)
Reducing weight and BMI following gestational diabetes: a systematic review and meta-analysis of digital and telemedicine interventions
In summary, this systematic review demonstrated the point estimate of the effect of the intervention on weight and BMI has potential to be clinically relevant but was not statistically significant (BMJ Open, Diabetes Research & Care)
Intrahepatic cholestasis of pregnancy: association with glycaemic control in gestational diabetes
Under the current treatment guidelines, ICP is not associated with clinically significant changes in glycaemic control in GDM. Significantly more women with both GDM and ICP developed preeclampsia (Diabetic Medicine)
Two decades since the fetal insulin hypothesis: what have we learned from genetics?
In summary, there is now ample evidence to support the idea that variants of certain genes which result in impaired pancreatic beta cell function and reduced insulin secretion contribute to both lower birthweight and higher type 2 diabetes risk in later life when inherited by the fetus (Diabetologia)
Characteristics and outcomes of pregnant women with type 1 or type 2 diabetes: a 5-year national population-based cohort study
Our data highlight persistent adverse pregnancy outcomes in women with type 1 or type 2 diabetes. Maternal glycaemia and BMI are the key modifiable risk factors. No maternity clinics were had appreciably better outcomes than any others, suggesting that health-care system changes are needed across all clinics (The Lancet Diabetes & Endocrinology)
Association between maternal triglycerides and disturbed glucose metabolism in pregnancy
Hypertriglyceridemia at the start of pregnancy is closely related to impaired insulin action and β-cell function. Women with hypertriglyceridemia have higher mean glucose levels in early- and mid-gestation. Pregnant women with elevated triglycerides in early pregnancy are at increased risk of developing gestational diabetes (Acta Diabetologica)
Endocrinology in the time of COVID-19: Diagnosis and management of gestational diabetes mellitus
We suggest pragmatic options for screening of GDM in a pandemic setting based on blood tests, and risk calculators applied to underlying risk factors (European Journal of Endocrinology)
Type 1 and type 2 diabetes after gestational diabetes: a 23 year cohort study
All women with GDM should be intensively monitored for a decade, after which the risk for type 1 diabetes is minimal. However, the incidence of type 2 diabetes remains linear, and therefore individualised lifelong follow-up is recommended (Diabetologia)
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)
Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial
We found several maternal glycaemic and neonatal adiposity benefits in the metformin group. Along with reduced maternal weight gain and insulin dosage and improved glycaemic control, the lower adiposity and infant size measurements resulted in fewer large infants but a higher proportion of small-for-gestational-age infants (The Lancet Diabetes & Endocrinology)
DTN-UK launch Best Practice Guide for Diabetes Technology in Pregnancy
Written by the leading experts in pregnancy in type 1 diabetes in the UK, the guide has useful tips, guidance and details about the use of insulin pumps, flash glucose monitoring and continuous glucose monitoring in pregnancy (ABCD)
Longitudinal changes in glucose metabolism in women with gestational diabetes, from late pregnancy to the postpartum period
In women with GDM, delivery was associated with improvement in both insulin sensitivity and insulin production within the first few days. Improvement in insulin production persisted for 6–12 weeks, but insulin sensitivity deteriorated slightly (Diabtologia)
The Utility of Lower Glycemic Targets for Treating Gestational Diabetes: A Retrospective Study
Lower glycemic targets did not produce large reductions in fetal overgrowth, but they were associated with a higher rate of inductions. As there were no observed differences in maternal or neonatal outcomes otherwise, aiming for lower glycemic targets in GDM is likely not cost-effective (Journal of Diabetes Research)
The Gut Microbiota in Women Suffering from Gestational Diabetes Mellitus with the Failure of Glycemic Control by Lifestyle Modification
Blautia, Faecalibacterium, and Eubacterium_hallii_group had important characteristic changes in the gut microbiota of women with GDM2. The relative abundance of Faecalibacterium, Blautia, and Eubacterium_hallii_group can discriminate GDM2 from GDM. Gut bacteria may participate in the pathological development of GDM2 through the PPAR signaling pathway, which should be conducted for further study in the future (Journal of Diabetes Research)
Screening for monogenic diabetes in primary care
The benefits and implications of life altering treatment such as termination of insulin administration are significant but little can be done without appropriate identification and referral (Primary Care Diabetes)
Modelling potential cost savings from use of real‐time continuous glucose monitoring in pregnant women with Type 1 diabetes
Routine use of RT‐CGM by pregnant women with type 1 diabetes, would result in substantial cost savings, mainly through reductions in NICU admissions and shorter duration of NICU care (Diabetes Medicine)
Impaired awareness of hypoglycemia: a new risk factor for adverse pregnancy outcomes in type 1 diabetes
Impaired awareness of hypoglycemia: a new risk factor for adverse pregnancy outcomes in type 1 diabetes (Diabetes Research and Clinical Practice)
Testing for type 1 diabetes autoantibodies in gestational diabetes mellitus (GDM): is it clinically useful?
From several epidemiological studies it appears that diabetes-related autoimmunity is not a main factor in the aetiology of GDM, accounting for less than 10% of all cases (BMC Endocrine Disorders)
- 1
- 2
- 3
- …
- 8
- Next Page »
Glycosmedia is also available as an App: